The Toll signaling pathway is involved in innate immunity in both flies and mammals. The Drosophila pathway, including the Toll receptor, Pelle kinase, and Dorsal transcription factor, regulates both dorsal-ventral polarity in the embryo and antimicrobial peptide production in adult flies. The human inflammatory cytokine IL-1 signals through the IL-1 receptor (whose cytoplasmic domain is homologous to that of Toll) and the Pelle homolog IRAK, ultimately activating NF k B, a rel protein homologous to Dorsal. Human Toll homologs also signal to NF k B(1). To investigate this pathway in C. elegans , we identified orthologs of four genes and generated deletion mutations for each:
tol-1 = Tol l receptor,
pik-1 = P elle/ I RAK k inase,
trf-1 = TR A F , and
ikb-1 = I k B . Worms with a deletion affecting all of
tol-1 except the N-terminal leucine-rich repeats arrest as small, deformed larvae, a phenotype rescued by the
tol-1 cosmid. However, a second
tol-1 deletion in the intracellular domain seems wild-type. Deletion mutants of the other three genes show no obvious phenotype. To test whether these deletion alleles affect putative C. elegans host defenses, we exposed worms to an Aureobacterium strain that causes anal infection and local tissue swelling (2). The swelling phenotype was not altered in the four viable mutants. We also examined the expression of
abf-1 and
abf-2 , which encode homologs of Ascaris antibacterial peptides (3).
abf-1 and
abf-2 expression was not altered in the four mutants compared to wild type, following either usual culture or Aureobacterium infection. Orthologs for other downstream elements of the Toll pathway, including NIK, IKK and NF k B (1), are conspicuously absent from the complete worm genome, suggesting that C. elegans has evolved an alternative transcriptional output for
tol-1 . Although our preliminary assays were negative, we cannot rule out a possible role for
tol-1 in worm immunity, given the dearth of known microbial pathogens of C. elegans . (1) Kopp ER & Medzhitov R, Curr Opin Immunol 1999; 11: 13. (2) Hodgkin J & Corneliussen B, WBG 1997; 15 (1):73. (3) Kato Y, WBG 1996; 14 (4):37.